🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,12 USD

Máx. histórico

89,55

117 días

Caída desde máximo

-23,93%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+11,89%

Cierre anterior

60,88

Rango de hoy

63,16 – 68,72

Volumen hoy

2.643.738

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,99%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 8 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
03/12/2024 53,33 54,16 49,28 50,29 -3,42% 9,16% 1.497.000
02/12/2024 52,08 52,97 49,19 52,07 +18,66% 7,25% 3.542.300
29/11/2024 44,77 45,38 43,18 43,88 -2,73% 4,90% 428.800
27/11/2024 47,00 47,23 44,20 45,11 -1,96% 6,44% 789.500
26/11/2024 43,54 47,24 43,25 46,01 +7,02% 9,16% 1.511.900
25/11/2024 43,81 44,85 42,94 42,99 -0,56% 4,37% 745.700
22/11/2024 43,03 44,10 42,74 43,23 +0,79% 3,16% 548.700
21/11/2024 42,09 43,41 41,21 42,89 +2,22% 5,23% 599.100
20/11/2024 39,38 42,79 38,26 41,96 +6,61% 11,50% 723.000
19/11/2024 39,36 40,06 38,71 39,36 +0,33% 3,43% 819.300
18/11/2024 39,14 39,86 38,65 39,23 +0,00% 3,09% 442.600
15/11/2024 42,74 42,74 38,94 39,23 -7,43% 8,89% 1.035.200
14/11/2024 44,28 44,28 41,95 42,38 -3,75% 5,26% 658.200
13/11/2024 44,68 45,65 43,55 44,03 -1,32% 4,70% 648.200
12/11/2024 44,28 44,87 43,48 44,62 -0,56% 3,14% 756.100
11/11/2024 44,46 46,98 44,46 44,87 +1,33% 5,67% 1.160.600
08/11/2024 45,64 46,55 43,64 44,28 +3,07% 6,38% 1.019.400
07/11/2024 43,33 44,56 42,82 42,96 -0,51% 4,02% 724.700
06/11/2024 42,49 43,27 41,70 43,18 +5,65% 3,69% 1.007.900
05/11/2024 40,36 41,08 39,89 40,87 +1,19% 2,95% 354.800
04/11/2024 39,99 41,32 39,41 40,39 -0,20% 4,78% 525.900
01/11/2024 39,97 40,75 39,64 40,47 +1,38% 2,78% 528.700
31/10/2024 40,49 41,07 39,70 39,92 -1,82% 3,38% 465.500
30/10/2024 42,93 42,98 40,62 40,66 -4,33% 5,49% 779.900
29/10/2024 40,30 42,51 40,30 42,50 +4,99% 5,48% 503.300
28/10/2024 41,25 41,66 40,37 40,48 -0,66% 3,13% 489.400
25/10/2024 41,75 42,04 40,59 40,75 -1,57% 3,46% 948.400
24/10/2024 42,70 43,40 41,07 41,40 -2,54% 5,46% 1.287.200
23/10/2024 38,96 42,61 38,18 42,48 +8,04% 11,37% 1.177.100
22/10/2024 38,21 40,09 38,21 39,32 +2,29% 4,91% 653.700